Vaxart Inc. (VXRT): Price and Financial Metrics


Vaxart Inc. (VXRT): $6.74

-0.14 (-2.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VXRT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 509

in industry

VXRT POWR Grades


  • Value is the dimension where VXRT ranks best; there it ranks ahead of 39.05% of US stocks.
  • VXRT's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • VXRT's current lowest rank is in the Stability metric (where it is better than 2.87% of US stocks).

VXRT Stock Summary

  • VXRT's price/sales ratio is 681.99; that's higher than the P/S ratio of 99.01% of US stocks.
  • With a year-over-year growth in debt of 219.85%, Vaxart Inc's debt growth rate surpasses 95.82% of about US stocks.
  • As for revenue growth, note that VXRT's revenue has grown -84.1% over the past 12 months; that beats the revenue growth of just 1.79% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Vaxart Inc are CRIS, SILC, LOGC, BLDP, and KDMN.
  • VXRT's SEC filings can be seen here. And to visit Vaxart Inc's official web site, go to vaxart.com.

VXRT Valuation Summary

  • VXRT's price/earnings ratio is -20.3; this is 155.62% lower than that of the median Healthcare stock.
  • Over the past 243 months, VXRT's price/earnings ratio has gone down 77.5.
  • VXRT's EV/EBIT ratio has moved down 67.6 over the prior 243 months.

Below are key valuation metrics over time for VXRT.

Stock Date P/S P/B P/E EV/EBIT
VXRT 2021-08-31 887.2 5.5 -20.3 -17.4
VXRT 2021-08-30 875.3 5.4 -20.1 -17.2
VXRT 2021-08-27 897.1 5.6 -20.6 -17.7
VXRT 2021-08-26 893.1 5.5 -20.5 -17.6
VXRT 2021-08-25 913.0 5.7 -20.9 -18.0
VXRT 2021-08-24 893.1 5.5 -20.5 -17.6

VXRT Growth Metrics

  • The 5 year cash and equivalents growth rate now stands at -23.44%.
  • Its 3 year net cashflow from operations growth rate is now at 42.59%.
  • Its 4 year revenue growth rate is now at -42.52%.
VXRT's revenue has moved down $12,161,000 over the prior 67 months.

The table below shows VXRT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 1.239 -49.772 -54.069
2021-03-31 1.65 -37.134 -46.93
2020-12-31 4.046 -23.75 -32.22
2020-09-30 7.606 -16.776 -24.768
2020-06-30 7.795 -11.849 -21.943
2020-03-31 7.357 -11.645 -18.603

VXRT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VXRT has a Quality Grade of D, ranking ahead of 8.66% of graded US stocks.
  • VXRT's asset turnover comes in at 0.007 -- ranking 402nd of 681 Pharmaceutical Products stocks.
  • ABEO, BCDA, and PCRX are the stocks whose asset turnover ratios are most correlated with VXRT.

The table below shows VXRT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.007 1 -2.885
2021-03-31 0.011 1 -7.113
2020-12-31 0.038 1 81.691
2020-09-30 0.099 1 12.466
2020-06-30 0.159 1 19.968
2020-03-31 0.174 1 -81.273

VXRT Price Target

For more insight on analysts targets of VXRT, see our VXRT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.50 Average Broker Recommendation 1.5 (Moderate Buy)

VXRT Stock Price Chart Interactive Chart >

Price chart for VXRT

VXRT Price/Volume Stats

Current price $6.74 52-week high $24.90
Prev. close $6.88 52-week low $3.50
Day low $6.41 Volume 5,036,700
Day high $6.82 Avg. volume 12,662,275
50-day MA $8.01 Dividend yield N/A
200-day MA $7.61 Market Cap 844.33M

Vaxart Inc. (VXRT) Company Bio


Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.


VXRT Latest News Stream


Event/Time News Detail
Loading, please wait...

VXRT Latest Social Stream


Loading social stream, please wait...

View Full VXRT Social Stream

Latest VXRT News From Around the Web

Below are the latest news stories about Vaxart Inc that investors may wish to consider to help them evaluate VXRT as an investment opportunity.

NVAX Stock: The Huge Reason Novavax Is Plunging Today

NVAX stock is struggling on Wednesday as investors process what's going on behind the scenes with Novavax's manufacturing.

Samuel O'Brient on InvestorPlace | October 20, 2021

Don’t Write Off Vaxart, As Its Oral Vaccine Still Has a Chance

VXRT stock is still worth a shot, as there's still big potential demand for a "no-needle" Covid-19 vaccine alternative.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | October 20, 2021

SHAREHOLDER ALERT: Morris Kandinov Investigating TSN, VXRT, APYX, and EHTH; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Tyson Foods, Inc., Vaxart, Inc., Apyx Medical Corporation, and eHealth, Inc. If you are a current owner of shares of any of these stocks, contact [email protected] or call (619) 708-3993. Tyson Foods, Inc. (NYSE: TSN) Shareholder Rights Investigation Morris Kandinov is investigating Tyson Foods, Inc. regarding corporate governance failures, possible bre

Yahoo | October 19, 2021

Can This COVID Vaccine Stock Help Make You Rich?

There are a handful of companies that dominate the coronavirus vaccine market. Vaccine hesitancy prevents many people from getting inoculated. One company looking to make headway into the vaccine-hesitant crowd is Vaxart (NASDAQ: VXRT).

Yahoo | October 16, 2021

Is Vaxart Stock a Buy Right Now? This Is What You Need to Know

The advent of Covid-19 also bought with it the rise of the coronavirus stocks. The phenomenon saw shares of previously unknown companies attain improbable heights in 2020, based on the potential to bring to market solutions to blunt the pandemic’s impact. For a while, hardly soared any higher than Vaxart (VXRT). The small vaccine maker boasts one big USP – its potential Covid-19 vaccine is in pill form, a godsend for the needle-shy.

Marty Shtrubel on TipRanks | October 13, 2021

Read More 'VXRT' Stories Here

VXRT Price Returns

1-mo -17.50%
3-mo -16.58%
6-mo -19.09%
1-year 19.50%
3-year 135.66%
5-year -55.28%
YTD 18.04%
2020 1,529.10%
2019 -81.36%
2018 -70.02%
2017 -53.66%
2016 -36.60%

Continue Researching VXRT

Here are a few links from around the web to help you further your research on Vaxart Inc's stock as an investment opportunity:

Vaxart Inc (VXRT) Stock Price | Nasdaq
Vaxart Inc (VXRT) Stock Quote, History and News - Yahoo Finance
Vaxart Inc (VXRT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0765 seconds.